Toxicity, Response and Survival in Older Patients with Metastatic Melanoma Treated with Checkpoint Inhibitors

N.A. de Glas*, E. Bastiaannet, F. van den Bos, S.P. Mooijaart, A.A.M. van der Veldt, K.P.M. Suijkerbuijk, M.J.B. Aarts, F.W.P.J. van den Berkmortel, C.U. Blank, M.J. Boers-Sonderen, A.J.M. van den Eertwegh, J.W.B. de Groot, J.B.A.G. Haanen, G.A.P. Hospers, H. Jalving, D. Piersma, R.S. van Rijn, A.J. ten Tije, G. Vreugdenhil, M.W.J.M. WoutersJ.E.A. Portielje, E.W. Kapiteijn

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Article number2826
Number of pages13
JournalCancers
Volume13
Issue number11
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • immunotherapy
  • melanoma
  • older adults
  • geriatric oncology
  • toxicity
  • response
  • CHEMOTHERAPY TOXICITY
  • GERIATRIC ASSESSMENT
  • COMBINED NIVOLUMAB
  • IPILIMUMAB
  • OUTCOMES
  • AGE
  • IMMUNOTHERAPY
  • SAFETY
  • COHORT
  • IMPACT

Cite this